ENGINEERED BOTULINUM NEUROTOXIN

Abstract Botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial botulinum serotype B(B-H,), comprising one or more substitution mutations corresponding to substitution mutations in serotype B, strain I, Vlll8M; Y1183M; E119IM; E11911;E9IQ; E119IT; S1199Y; S11...

Full description

Saved in:
Bibliographic Details
Main Authors Peng, Lisheng, Stenmark, Pal Erik Gustav, Berntsson, Ronnie Per-Arne, Dong, Min
Format Patent
LanguageEnglish
Published 10.10.2019
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Abstract Botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial botulinum serotype B(B-H,), comprising one or more substitution mutations corresponding to substitution mutations in serotype B, strain I, Vlll8M; Y1183M; E119IM; E11911;E9IQ; E119IT; S1199Y; S1199F; S1199L; SI 20 IV; or combinations thereof. Specific combination mutations include El 191M and SI 199L, El 191M and SI 199Y, El 191M and SI 199F, El 191Q and SI 199L, El 191Q and S 1199Y, or E 1191 Q and S 1199F. Other substitution mutations are also disclosed. Isolated modified receptor binding domains, chimeric molecules, pharmaceutical compositions, and methods of using the same are also disclosed.
Bibliography:Application Number: AU20180200409